Since the approval of Luxturna, there has been a wave of gene therapies advancing in clinical trials to treat genetic vision ...

On the occasion of its deal with Cure51, find out about NVIDIA's biotech strategy as it gets more and more involved in the ...

Delve into what the new CRISPR tool, CAST, has to offer. CRISPR-associated transposases are already gaining traction in ...